Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment

Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment - case report

Published:2010-12 Issue:1 Volume:10 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Hsieh Chen-Hsi,Chang Hou-Tai,Lin Shih-Chiang,Chen Yu-Jen,Wang Li-Ying,Hsieh Yen-Ping,Chen Chien-An,Chong Ngot-Swan,Lin Shoei Long,Chen Chun-Yi,Shueng Pei-Wei

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/1471-2407-10-696.pdf

Reference21 articles.

1. Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM, et al: Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol. 2007, 25 (7): 760-766. 10.1200/JCO.2006.07.5754.

2. Hodge W, Tome WA, Jaradat HA, Orton NP, Khuntia D, Traynor A, Weigel T, Mehta MP: Feasibility report of image guided stereotactic body radiotherapy (IG-SBRT) with tomotherapy for early stage medically inoperable lung cancer using extreme hypofractionation. Acta Oncol. 2006, 45 (7): 890-896. 10.1080/02841860600907329.

3. Slotman BJ, Njo KH, de Jonge A, Meijer OW, Karim AB: Hypofractionated radiation therapy in unresectable stage III non-small cell lung cancer. Cancer. 1993, 72 (6): 1885-1893. 10.1002/1097-0142(19930915)72:6<1885::AID-CNCR2820720616>3.0.CO;2-7.

4. Choong NW, Mauer AM, Haraf DJ, Lester E, Hoffman PC, Kozloff M, Lin S, Dancey JE, Szeto L, Grushko T, et al: Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008, 3 (9): 1003-1011. 10.1097/JTO.0b013e31818396a4.

5. Yorke ED, Jackson A, Rosenzweig KE, Merrick SA, Gabrys D, Venkatraman ES, Burman CM, Leibel SA, Ling CC: Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2002, 54 (2): 329-339. 10.1016/S0360-3016(02)02929-2.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combining chemotherapy and tislelizumab with preoperative split-course hypofraction radiotherapy for locally advanced rectal cancer: study protocol of a prospective, single-arm, phase II trial;BMJ Open;2023-03

2. Systemic therapy‐based split‐course stereotactic body radiation therapy;Precision Radiation Oncology;2022-11-27

3. Chemotherapy-based split stereotactic body radiation therapy for borderline resectable and locally advanced pancreatic cancer: study protocol of a prospective, single-arm phase II trial;BMJ Open;2020-11

4. Robust combination of liver stereotactic body radiotherapy modulates pharmacokinetics of sorafenib toward preferable parameters;Scientific Reports;2020-06-12

5. Fatal Radiation Pneumonitis: Literature Review and Case Series;Advances in Radiation Oncology;2020-03